Celexa® (citalopram hydrobromide) Tablets/Oral Solution
... concentrations observed after a single dose. The tablet and oral solution dosage forms of citalopram HBr are bioequivalent. Absorption and Distribution Following a single oral dose (40 mg tablet) of citalopram, peak blood levels occur at about 4 hours. The absolute bioavailability of citalopram was ...
... concentrations observed after a single dose. The tablet and oral solution dosage forms of citalopram HBr are bioequivalent. Absorption and Distribution Following a single oral dose (40 mg tablet) of citalopram, peak blood levels occur at about 4 hours. The absolute bioavailability of citalopram was ...
KETOCONAZOLE TABLETS USP 200 mg Rx Only WARNING
... ketoconazole as high as 80 mg/kg produced no mutation in any stage of germ cell development. The Ames Salmonella microsomal activator assay was also negative. A long term feeding study in Swiss Albino mice and in Wistar rats showed no evidence of oncogenic activity. Pregnancy: Teratogenic effects: P ...
... ketoconazole as high as 80 mg/kg produced no mutation in any stage of germ cell development. The Ames Salmonella microsomal activator assay was also negative. A long term feeding study in Swiss Albino mice and in Wistar rats showed no evidence of oncogenic activity. Pregnancy: Teratogenic effects: P ...
Antimicrobial Dosing for Adults in Renal Impairment
... NUH Antibiotic Guidelines Committee NUH Drugs and Therapeutics Committee ...
... NUH Antibiotic Guidelines Committee NUH Drugs and Therapeutics Committee ...
Product Monograph Template - Standard
... Pediatrics§ (< 12 years of age): AERIUS DUAL ACTION 12 HOUR is not recommended for use in children below the age of 12 years due to lack of data on safety and efficacy. Geriatrics§ (≥ 65 years of age): The number of patients 65 years of age and above treated with AERIUS DUAL ACTION 12 HOUR were too ...
... Pediatrics§ (< 12 years of age): AERIUS DUAL ACTION 12 HOUR is not recommended for use in children below the age of 12 years due to lack of data on safety and efficacy. Geriatrics§ (≥ 65 years of age): The number of patients 65 years of age and above treated with AERIUS DUAL ACTION 12 HOUR were too ...
NEW ZEALAND DATA SHEET SERETIDE® Inhaler (with
... pre-existing cardiovascular disorders. Lower serum potassium A transient decrease in serum potassium may occur with all sympathomimetic drugs at higher therapeutic doses. Therefore, SERETIDE should be used with caution in patients predisposed to low levels of serum potassium. Diabetes mellitus There ...
... pre-existing cardiovascular disorders. Lower serum potassium A transient decrease in serum potassium may occur with all sympathomimetic drugs at higher therapeutic doses. Therefore, SERETIDE should be used with caution in patients predisposed to low levels of serum potassium. Diabetes mellitus There ...
Conversion from prednisone po to hydrocortisone iv
... Body and the remainder diversity among the cases. Has been regarded as worthy of ...
... Body and the remainder diversity among the cases. Has been regarded as worthy of ...
Adobe Acrobat version of Pharm Cards for CNS section
... anesthetic properties from block of Na+ & Ca2+ channels → ↓ rate of rise of action potential, failure to propagate action potential, eventual conduction block. Smaller, unmyelinated fibers are more easily blocked and remain blocked longer. Absorption: : Rapidly absorbed IV & oral. IV absorption can ...
... anesthetic properties from block of Na+ & Ca2+ channels → ↓ rate of rise of action potential, failure to propagate action potential, eventual conduction block. Smaller, unmyelinated fibers are more easily blocked and remain blocked longer. Absorption: : Rapidly absorbed IV & oral. IV absorption can ...
Valproate Learning Objectives Outline Indications
... documented cases from only Germany over 10 years corroborates that the occurrence of this severe side effect is under reported.” ...
... documented cases from only Germany over 10 years corroborates that the occurrence of this severe side effect is under reported.” ...
Glaucoma
... other topical ophthalmic drug products to lower intraocular pressure. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart ...
... other topical ophthalmic drug products to lower intraocular pressure. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart ...
Relative potency of proton-pump inhibitors-comparison of
... Institute of Pharmacology of Natural Products and Clinical Pharmacology, University of Ulm, ...
... Institute of Pharmacology of Natural Products and Clinical Pharmacology, University of Ulm, ...
I2326E-IF2326E- Savage NITROBID
... administered to a pregnant woman or whether it can affect reproductive capacity. Nitroglycerin should be given to a pregnant woman only if clearly needed. Nursing Mothers: It is not known whether nitroglycerin is excreted in human milk. Because many drugs are excreted in human milk, caution should b ...
... administered to a pregnant woman or whether it can affect reproductive capacity. Nitroglycerin should be given to a pregnant woman only if clearly needed. Nursing Mothers: It is not known whether nitroglycerin is excreted in human milk. Because many drugs are excreted in human milk, caution should b ...
AusPAR: Zonisamide
... In subjects with renal impairment, renal clearance of single doses of zonisamide was positively correlated with creatinine clearance. The plasma AUC of zonisamide was increased by 35% in subjects with creatinine clearance < 20mL/min. Patients with an impaired liver function: The pharmacokinetics of ...
... In subjects with renal impairment, renal clearance of single doses of zonisamide was positively correlated with creatinine clearance. The plasma AUC of zonisamide was increased by 35% in subjects with creatinine clearance < 20mL/min. Patients with an impaired liver function: The pharmacokinetics of ...
Vytorin - Merck.com
... The dose of VYTORIN should not exceed 10/10 mg/day [see Warnings and Precautions (5.1), Drug Interactions (7.3), and Clinical Pharmacology (12.3)]. Patients taking Amiodarone, Amlodipine or Ranolazine The dose of VYTORIN should not exceed 10/20 mg/day [see Warnings and Precautions (5.1), Drug In ...
... The dose of VYTORIN should not exceed 10/10 mg/day [see Warnings and Precautions (5.1), Drug Interactions (7.3), and Clinical Pharmacology (12.3)]. Patients taking Amiodarone, Amlodipine or Ranolazine The dose of VYTORIN should not exceed 10/20 mg/day [see Warnings and Precautions (5.1), Drug In ...
Pharmacokinetic interaction studies of atosiban with labetalol
... fact that some antihypertensives, such as diuretics and angiotensin converting enzyme (ACE) inhibitors, are contraindicated during pregnancy due to fetal toxicity or side effects.9 Therefore, due to the frequent co-administration of atosiban and labetalol, it is important to assess the risk of a pha ...
... fact that some antihypertensives, such as diuretics and angiotensin converting enzyme (ACE) inhibitors, are contraindicated during pregnancy due to fetal toxicity or side effects.9 Therefore, due to the frequent co-administration of atosiban and labetalol, it is important to assess the risk of a pha ...
Guideline for the use of clopidogrel in combination
... lesion anatomy will influence the decision. It is recommended that all such cases should be discussed with the interventional cardiologist. Non-ST elevation ACS patients who have not undergone PCI Clopidogrel prolongs bleeding time and should be used with caution in patients who have conditions with ...
... lesion anatomy will influence the decision. It is recommended that all such cases should be discussed with the interventional cardiologist. Non-ST elevation ACS patients who have not undergone PCI Clopidogrel prolongs bleeding time and should be used with caution in patients who have conditions with ...
REVIEW ON CONVENTIONAL AND NOVEL TECHNIQUES FOR TREATMENT OF ALVEOLAR OSTEITIS
... From literature survey it is observed that there is no proper dosage form for treatment and prevention of AO. Thus developing dosage forms which would provide a sustained drug release, reduce bacterial infection, help in wound healing , act as haemostatic and provide a better patient compliance with ...
... From literature survey it is observed that there is no proper dosage form for treatment and prevention of AO. Thus developing dosage forms which would provide a sustained drug release, reduce bacterial infection, help in wound healing , act as haemostatic and provide a better patient compliance with ...
UKMi FAQ 18 - NHS Evidence Search
... This Medicines Q&A aims to review the data available to assist decision-making when choosing between the two agents. ...
... This Medicines Q&A aims to review the data available to assist decision-making when choosing between the two agents. ...
Zeldox capsule, hard ENG SmPC
... controlled clinical trials, the combination of ziprasidone plus lithium has not demonstrated an increased clinical risk, compared to lithium alone. There are limited data on co-medication with the mood stabiliser carbamazepine . A pharmacokinetic interaction of ziprasidone with valproate is unlikely ...
... controlled clinical trials, the combination of ziprasidone plus lithium has not demonstrated an increased clinical risk, compared to lithium alone. There are limited data on co-medication with the mood stabiliser carbamazepine . A pharmacokinetic interaction of ziprasidone with valproate is unlikely ...
ATryn : EPAR
... higher in association with type I deficiency and type II-a deficiency, where the mutation affects the reactive site, as compared to type II-b deficiency where the mutation affects the heparin-binding site. The genetic defect of the AT gene is located at chromosome 1q23-25. Type I deficiencies are pr ...
... higher in association with type I deficiency and type II-a deficiency, where the mutation affects the reactive site, as compared to type II-b deficiency where the mutation affects the heparin-binding site. The genetic defect of the AT gene is located at chromosome 1q23-25. Type I deficiencies are pr ...
Vedani Nicola
... treatment of documented life-threatening ventricular arrhythmias, such as sustained ventricular tachycardia. PROCAN SR may also be used for the treatment of patients with documented symptomatic ventricular arrhythmias when the symptoms are of sufficient severity to require treatment. Because of the ...
... treatment of documented life-threatening ventricular arrhythmias, such as sustained ventricular tachycardia. PROCAN SR may also be used for the treatment of patients with documented symptomatic ventricular arrhythmias when the symptoms are of sufficient severity to require treatment. Because of the ...
Hydromorphone Hydrochloride Injection, USP, CII (1 mg/mL)
... pain, and depends upon a comprehensive assessment of the patient. Individualize treatment in every case, using non-opioid analgesics, opioids on an as needed basis and/or combination products, and chronic opioid therapy in a progressive plan of pain management such as outlined by the World Health Or ...
... pain, and depends upon a comprehensive assessment of the patient. Individualize treatment in every case, using non-opioid analgesics, opioids on an as needed basis and/or combination products, and chronic opioid therapy in a progressive plan of pain management such as outlined by the World Health Or ...
Imodium Liquid, 2 mg/15 ml Oral Solution PL 15513/0182
... All product literature (SmPC, PIL and labelling) are satisfactory. The package leaflet was submitted to the MHRA along with results of consultations with target patient groups ("user testing"), in accordance with Article 59 of Council Directive 2001/83/EC. The results indicate that the package leafl ...
... All product literature (SmPC, PIL and labelling) are satisfactory. The package leaflet was submitted to the MHRA along with results of consultations with target patient groups ("user testing"), in accordance with Article 59 of Council Directive 2001/83/EC. The results indicate that the package leafl ...
MS Contin - Purdue Pharma
... MS Contin must be swallowed whole (not cut, broken, chewed, dissolved or crushed) due to the risk of fatal morphine overdose. Only the 200 mg tablet is scored and may be broken in half. The half tablet must also be swallowed intact. ...
... MS Contin must be swallowed whole (not cut, broken, chewed, dissolved or crushed) due to the risk of fatal morphine overdose. Only the 200 mg tablet is scored and may be broken in half. The half tablet must also be swallowed intact. ...
March 2015 - Positive Recommendations
... • that there is the high clinical need for all oral interferon-free treatments of CHC to be made available on the PBS, • that these treatments would be cost-effective at $15,000/QALY range and that there was no basis on which to recommend that any one treatment be more expensive than another, • ther ...
... • that there is the high clinical need for all oral interferon-free treatments of CHC to be made available on the PBS, • that these treatments would be cost-effective at $15,000/QALY range and that there was no basis on which to recommend that any one treatment be more expensive than another, • ther ...
HIGHLIGHTS OF PRESCRIBING INFORMATION These
... diabetes, in patients with diabetic nerve disease, in patients using medications that block the sympathetic nervous system (e.g., beta-blockers) [see Drug Interactions (7)], or in patients who experience recurrent hypoglycemia. Risk Factors for Hypoglycemia The risk of hypoglycemia after an injectio ...
... diabetes, in patients with diabetic nerve disease, in patients using medications that block the sympathetic nervous system (e.g., beta-blockers) [see Drug Interactions (7)], or in patients who experience recurrent hypoglycemia. Risk Factors for Hypoglycemia The risk of hypoglycemia after an injectio ...
Ofloxacin
Ofloxacin is a synthetic antibiotic of the fluoroquinolone drug class considered to be a second-generation fluoroquinolone.Ofloxacin was first patented in 1982 (European Patent Daiichi) and received approval from the U.S. Food and Drug Administration (FDA) on December 28, 1990. Ofloxacin is sold under a wide variety of brand names as well as generic drug equivalents, for oral and intravenous administration. Ofloxacin is also available for topical use, as eye drops and ear drops (marketed as Ocuflox and Floxin Otic respectively in the United States and marketed as Optiflox, eylox respectively in Jordan and Saudi Arabia).Ofloxacin is a racemic mixture, which consists of 50% levofloxacin (the biologically active component) and 50% of its “mirror image” or enantiomer dextrofloxacin.Ofloxacin has been associated with adverse drug reactions, such as tendon damage (including spontaneous tendon ruptures) and peripheral neuropathy (which may be irreversible); tendon damage may manifest long after therapy had been completed, and, in severe cases, may result in lifelong disabilities.